What's New Since 2002? The primary objective in selecting a treatment strategy in UA/NSTEMI is to choose an approach likely to yield the best long-term clinical outcome. Two treatment pathways ...

The committee also suggests that the reversible non-thienopyridine P2Y12 receptor antagonist ticagrelor may play a future role in patients with unstable angina/NSTEMI based on results from the PLATO ...

A non-ST segment elevation myocardial infarction, also called an NSTEMI or a non-STEMI, is a type of heart attack. While it's often less damaging to your heart than a STEMI, it's still a serious ...

Still, the ideal treatment of cocaine-associated NSTEMI isn’t clear: there are no randomized, placebo-controlled trials in this setting. In 2014, the American College of Cardiology (ACC) and AHA ...

In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.

NSTEMI stands for non-ST segment elevation myocardial infarction, which is a type of heart attack. Compared to the more common type of heart attack known as STEMI, an NSTEMI is typically less ...

Several STEMI/NSTEMI performance measures have been proposed by ACC/AHA, and endorsed by multiple organizations, to ensure effective, timely, safe, efficient, and patient-centered medical care ...

In November 2009, Effient also was added as a Class I recommended treatment in AHA/ACC/SCAI clinical guidelines for patients with UA or NSTEMI receiving PCI and for patients with ST elevation ...

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) recently reviewed pivotal trials of the last 5 years and released an update to the 2002 UA/NSTEMI ...